Skip to main content
NCBI home page
Gut logoLink to Gut
. 1987 Sep;28(9):1084–1089. doi: 10.1136/gut.28.9.1084

Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis.

H A Mardini 1, D C Lindsay 1, C M Deighton 1, C O Record 1
PMCID: PMC1433240  PMID: 3678967

Abstract

It has been suggested that polymer coating might retard jejunal absorption of 5-amino salicylic acid (5-ASA) and thus promote delivery to its colonic site of action. Twenty three patients with active (nine), or quiescent (14) ulcerative colitis were given either uncoated or coated 5-ASA (Asacol) 400 mg qds for one to three weeks, after which they ingested five 1.5 ml dialysis membrane sachets which were recovered from the stool in the next 72 hours. After one week of treatment the concentration of 5-ASA in the faecal dialysate, urine, and fasting plasma in those receiving the coated and uncoated preparations were respectively: 25.4 +/- 5.1 compared with 1.2 +/- 0.4 mmol/l (p less than 0.001); 0.34 +/- 0.21 compared with 0.70 +/- 0.29 mmol/24h (NS) and 11.1 +/- 4.2 compared with 0.07 +/- 0.03 mumol/l (p less than 0.02). Faecal excretion of the drug appeared to be greater in patients with active colitis than in those with quiescent disease. Thus coating with pH dependent methacrylic acid copolymer B is a very effective method of promoting delivery of 5-ASA to the colon, stool dialysate concentrations being 20 fold more than those in controls. Increased trough plasma concentrations in the polymer coating group probably reflect delayed intestinal absorption but no evidence of plasma accumulation after 21 days of therapy was found.

Full text

PDF
1084

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Austin C. A., Cann P. A., Jones T. H., Holdsworth C. D. Exacerbation of diarrhoea and pain in patients treated with 5-aminosalicylic acid for ulcerative colitis. Lancet. 1984 Apr 21;1(8382):917–918. doi: 10.1016/s0140-6736(84)91386-2. [DOI] [PubMed] [Google Scholar]
  2. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  3. Campieri M., Lanfranchi G. A., Bazzocchi G., Brignola C., Sarti F., Franzin G., Battocchia A., Labo G., Dal Monte P. R. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet. 1981 Aug 8;2(8241):270–271. doi: 10.1016/s0140-6736(81)90523-7. [DOI] [PubMed] [Google Scholar]
  4. Campieri M., Lanfranchi G. A., Boschi S., Brignola C., Bazzocchi G., Gionchetti P., Minguzzi M. R., Belluzzi A., Labò G. Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut. 1985 Apr;26(4):400–405. doi: 10.1136/gut.26.4.400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cann P. A., Holdsworth C. D. Reversal of male infertility on changing treatment from sulphasalazine to 5-aminosalicylic acid. Lancet. 1984 May 19;1(8386):1119–1119. doi: 10.1016/s0140-6736(84)92526-1. [DOI] [PubMed] [Google Scholar]
  6. Dew M. J., Ebden P., Kidwai N. S., Lee G., Evans B. K., Rhodes J. Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis. Br J Clin Pharmacol. 1984 Apr;17(4):474–476. doi: 10.1111/j.1365-2125.1984.tb02375.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dew M. J., Harries A. D., Evans B. K., Rhodes J. Treatment of ulcerative colitis with oral 5-aminosalicyclic acid in patients unable to take sulphasalazine. Lancet. 1983 Oct 1;2(8353):801–801. doi: 10.1016/s0140-6736(83)92341-3. [DOI] [PubMed] [Google Scholar]
  8. Dew M. J., Harries A. D., Evans N., Evans B. K., Rhodes J. Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. Br Med J (Clin Res Ed) 1983 Jul 2;287(6384):23–24. doi: 10.1136/bmj.287.6384.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dew M. J., Hughes P., Harries A. D., Williams G., Evans B. K., Rhodes J. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J (Clin Res Ed) 1982 Oct 9;285(6347):1012–1012. doi: 10.1136/bmj.285.6347.1012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dew M. J., Ryder R. E., Evans N., Evans B. K., Rhodes J. Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis. Br J Clin Pharmacol. 1983 Aug;16(2):185–187. doi: 10.1111/j.1365-2125.1983.tb04983.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Friedman G. Sulfasalazine and new analogues. Am J Gastroenterol. 1986 Feb;81(2):141–144. [PubMed] [Google Scholar]
  12. Klotz U. Clinical efficacy of oral 5-aminosalicylic acid in the treatment of inflammatory bowel disease. Am J Gastroenterol. 1985 Aug;80(8):660–660. [PubMed] [Google Scholar]
  13. Klotz U., Maier K., Fischer C., Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med. 1980 Dec 25;303(26):1499–1502. doi: 10.1056/NEJM198012253032602. [DOI] [PubMed] [Google Scholar]
  14. Peppercorn M. A., Goldman P. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology. 1973 Feb;64(2):240–245. [PubMed] [Google Scholar]
  15. Shaffer J. L., Kershaw A., Berrisford M. H. Sulphasalazine-induced infertility reversed on transfer to 5-aminosalicylic acid. Lancet. 1984 Jun 2;1(8388):1240–1240. doi: 10.1016/s0140-6736(84)91724-0. [DOI] [PubMed] [Google Scholar]
  16. Wolthers B. G., Meijer S., Tepper T., Hayer M., Elzinga H. The determination of oxalate in haemodialysate and plasma: a means to detect and study 'hyperoxaluria' in haemodialysed patients. Clin Sci (Lond) 1986 Jul;71(1):41–47. doi: 10.1042/cs0710041. [DOI] [PubMed] [Google Scholar]
  17. van Hees P. A., Bakker J. H., van Tongeren J. H. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut. 1980 Jul;21(7):632–635. doi: 10.1136/gut.21.7.632. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES